Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
Codexis, Inc. reported the final voting results from its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi as directors for three-year terms expiring at the 2029 annual meeting.
Stockholders also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 74,561,400 votes for, 106,175 against, and 70,905 abstentions. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
CODEXIS, INC. director Parker H. Stewart reported receiving a stock option award for 66,350 shares of common stock. The option has an exercise price of $2.48 per share and expires on June 17, 2036, with 66,350 derivative securities held after the grant.
According to the terms, the option vests and becomes exercisable for all 66,350 shares on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service as a director on that vesting date.
CODEXIS, INC. director Cynthia Collins received a grant of stock options covering 66,350 shares of common stock at an exercise price of $2.48 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, and expire in 2036.
CODEXIS, INC. director Christos Richards received a grant of stock options covering 66,350 shares of common stock at an exercise price of $2.48 per share. The options were awarded at no cost, vesting in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service, and will expire on June 17, 2036.
CODEXIS, INC. director David V. Smith received a grant of stock options covering 66,350 shares of common stock. The options have an exercise price of $2.48 per share and expire on June 17, 2036.
According to the footnote, the award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, as long as Smith continues serving as a director through that vesting date. After this grant, his reported option holdings from this award total 66,350 shares.
CODEXIS, INC. director Rahul Singhvi was granted a stock option covering 66,350 shares of common stock. The option has an exercise price of $2.48 per share and expires on June 17, 2036.
The award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, as long as he continues serving as a director on that vesting date. Following this grant, his option holdings from this award total 66,350 shares.
CODEXIS, INC. director Esther Martinborough reported receiving a stock option grant covering 66,350 shares of common stock at an exercise price of $2.48 per share. The option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continued board service, and expires on June 17, 2036. Following this grant, she holds options for 66,350 shares directly.
CODEXIS, INC. director Stephen George Dilly reported receiving a grant of stock options. The award covers 66,350 options to buy Common Stock at an exercise price of $2.48 per share, with 66,350 derivative securities shown as held after the transaction.
These options were granted as compensation, not bought on the open market, and carry no upfront cost to the director. They vest and become exercisable for all shares on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues serving as a director through that vesting date.
CODEXIS, INC. director Raymond De Vre received a grant of stock options covering 66,350 shares of common stock. The options have an exercise price of $2.48 per share and expire on June 17, 2036. The award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service as a director. Following this grant, De Vre holds 66,350 stock options directly.
CODEXIS, INC. director Raymond De Vre reported an open-market sale of common stock primarily to cover taxes from recently vested equity awards. He sold 2,605 shares at $2.37 per share on June 11, 2026. After this transaction, he holds 84,811 shares directly, including 31,897 Restricted Stock Units, so he retains a substantial continuing stake in the company.